Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Detalles Bibliográficos
Autores principales: McIntyre, Kristi, O’Shaughnessy, Joyce, Schwartzberg, Lee, Glück, Stefan, Berrak, Erhan, Song, James X., Cox, David, Vahdat, Linda T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Erratum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643585/
http://dx.doi.org/10.1007/s10549-014-3010-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643585/
http://dx.doi.org/10.1007/s10549-014-3010-y

Ejemplares similares